An observational study in Interviews, sponsored by University Hospital, Rouen. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by University Hospital, Rouen · Observational
In adult emergency departments, the number of admissions for adverse effects related to opioid use is constantly increasing. However, the massive flow of patients, lack of time, and rapid rotation of physicians in this department do not favor the transmission of in-depth information on the proper use of these therapies to the patient. In addition, this therapeutic class tends to worry patients. Public authorities as well as the medical profession are concerned about the potential adverse effects of morphine, but also the potential misuse, or even overdose, which can be fatal for the patient. Interventions by the community pharmacist in the fight against this misuse seem interesting, but an intervention upstream of potential problems of proper use seems even more relevant to us. Recent studies have shown the strong interest of the pharmacist in a multidisciplinary team on pain and opioids, both at the local level with studies conducted at the Rouen University Hospital by C. LATTARD et al. in rheumatology and E.BARAT et al. in outpatient surgery. It also appears that knowledge on the subject is satisfactory. Work conducted by Winstanley et al. shows that the intervention of a pharmacist in the emergency department seems relevant in terms of patient knowledge and satisfaction, and entirely feasible.
This study aims to measure the clinical impact of a hospital pharmacist when initiating opioid treatment for acute non-cancer pain in the Short Stay Hospitalization Units (UHCD) and Downstream Hospitalization Units (UHA) of the adult emergency department at Rouen University Hospital.
Pharmacy interviews will be offered to patients meeting the inclusion criteria. These 15- to 30-minute interviews will aim to present the tools implemented by the Rouen University Hospital pharmacy team. Several topics will be discussed, including: treatment optimization, potential adverse effects and what to do if they occur, the differences between immediate-release (IR) and extended-release (LP) forms, what to do if a dose is missed, the risks of overdose and addiction, and storage methods.
The objective of this project is, firstly, to improve patient satisfaction with their care and, secondly, to better understand the treatment, thus enabling more optimal use.
122 studies on the registry are indexed under Tooth, Impacted; 15 are open to participants now.
This study's enrollment of 100 is close to the median of 105 across 31 observational studies indexed under Tooth, Impacted.
Browse Tooth, Impacted studies →University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients over 18 years of age with opioid analgesic treatment upon discharge from hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evaluation of satisfaction with a pharmaceutical interview for acute pain
To assess satisfaction with pharmaceutical care for acute non-cancer pain in short-term hospitalization units (UHCD) and emergency downstream hospitalization units (UHA) during a telephone call to the patient 7 days after discharge from hospital. This satisfaction will be quantified as a percentage from 0 to 100%.
Time frame: Day 7
Evaluation of the relevance and effectiveness of pharmaceutical maintenance against pain
Patient satisfaction with pharmaceutical pain management on day 3 will be assessed during a telephone call to the patient 3 days after discharge from hospital. This satisfaction will be quantified as a percentage from 0 to 100%.
Time frame: Day 3
Evaluation of the relevance and effectiveness of pharmaceutical maintenance against pain
The average pain assessment on admission, discharge, day 3 and day 7 will be evaluated using a numerical scale from 0 to 10.
Time frame: Day 3 and Day 7
Plan to share: No — The data provided will be the property of the sponsor and will be used solely for its own research activities.
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Nov 2024, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.